Analysts Set Sana Biotechnology, Inc. (NASDAQ:SANA) Price Target at $10.80

Sana Biotechnology, Inc. (NASDAQ:SANA) has been given a consensus rating of “Moderate Buy” by the seven brokerages that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $10.80.

Several equities analysts have recently commented on SANA shares. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Sana Biotechnology in a research report on Tuesday, March 18th. Jefferies Financial Group assumed coverage on Sana Biotechnology in a research report on Friday, March 14th. They issued a “buy” rating and a $7.00 target price for the company. TD Cowen raised Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, Citizens Jmp raised shares of Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 price objective for the company in a report on Tuesday, March 18th.

Sana Biotechnology Price Performance

NASDAQ:SANA opened at $1.81 on Tuesday. Sana Biotechnology has a 1-year low of $1.26 and a 1-year high of $10.50. The stock has a market cap of $407.30 million, a P/E ratio of -1.29 and a beta of 1.78. The firm has a 50-day moving average of $2.35 and a two-hundred day moving average of $2.78.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Monday, March 17th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.02. As a group, equities analysts expect that Sana Biotechnology will post -1.16 earnings per share for the current year.

Institutional Investors Weigh In On Sana Biotechnology

A number of hedge funds have recently added to or reduced their stakes in the stock. Cerity Partners LLC bought a new position in shares of Sana Biotechnology during the fourth quarter worth about $25,000. Tower Research Capital LLC TRC raised its holdings in shares of Sana Biotechnology by 229.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company’s stock valued at $25,000 after buying an additional 10,548 shares during the last quarter. Syon Capital LLC acquired a new position in shares of Sana Biotechnology during the fourth quarter worth approximately $27,000. Wilmington Savings Fund Society FSB acquired a new stake in Sana Biotechnology in the 3rd quarter valued at approximately $29,000. Finally, Ameriprise Financial Inc. bought a new stake in Sana Biotechnology during the 4th quarter valued at $29,000. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.